Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for antigen-specific cytotoxic T lymphocyte response stimulation under leukopenic conditions

Vaccine

Volumn 30, Issue 19, 2012, Pages 2963-2972

  Oliver, Liliana ^a   Fernández, Audry ^a   Raymond, Judith ^a   López Requena, Alejandro ^a   Fernández, Luis E ^a   Mesa, Circe ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Adjuvant; Immunomodulator; Immunosuppression; Leukopenia; VSSP

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOLOGICAL ADJUVANT; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEOLIPOSOME;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LEUKOPENIA; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; MYELOID DENDRITIC CELL; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; LEUKOPENIA; MICE; MICE, INBRED C57BL; NEISSERIA MENINGITIDIS; OVALBUMIN; PROTEOLIPIDS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84859424756     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.054     Document Type: Article

References (49)

1. + T cell frequencies but limits proliferative capacity in chronically infected children. J Immunol 2003, 170(11):5786-5792.
2. Crawford J., Dale D.C., Kuderer N.M., Culakova E., Poniewierski M.S., Wolff D., et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008, 6(2):109-118.
3. Ljungman P., Engelhard D., de la Camara R., Einsele H., Locasciulli A., Martino R., et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005, 35(8):737-746.
4. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 2003, 21:807-839.
5. Todryk S. A sense of tumour for the immune system. Immunology 2002, 107(1):1-4.
6. Mesa C., Fernandez L.E. Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol 2004, 82(6):644-650.
7. Warger T., Osterloh P., Rechtsteiner G., Fassbender M., Heib V., Schmid B., et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006, 108(2):544-550.
8. Estevez F., Carr A., Solorzano L., Valiente O., Mesa C., Barroso O., et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 1999, 18(1-2):190-197.
9. Mesa C., de Leon J., Fernandez L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine 2006, 24(14):2692-2699.
10. Mesa C., De Leon J., Rigley K., Fernandez L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 2004, 22(23-24):3045-3052.
11. Carr A., Rodriguez E., Arango Mdel C., Camacho R., Osorio M., Gabri M., et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol 2003, 21(6):1015-1021.
12. ® LeukoCIM (G-CSF) in patients with neutropenia after chemotherapy. Rev Cubana Farm 2011, 45(1):19-33.
13. Toes R.E., Offringa R., Feltkamp M.C., Visseren M.J., Schoenberger S.P., Melief C.J., et al. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. Behring Inst Mitt 1994, 94:72-86.
14. Verdijk R.M., Mutis T., Esendam B., Kamp J., Melief C.J., Brand A., et al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 1999, 163(1):57-61.
15. + cytotoxic T lymphocytes. Int Immunol 2004, 16(1):55-63.
16. Kuderer N.M., Dale D.C., Crawford J. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007, 25(21):3158-3167.
17. Ladenstein R., Valteau-Couanet D., Brock P., Yaniv I., Castel V., Laureys G., et al. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol 2010, 28(21):3516-3524.
18. Salem M.L., Diaz-Montero C.M., Al-Khami A.A., El-Naggar S.A., Naga O., Montero A.J., et al. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol 2009, 182(4):2030-2040.
19. Schwartz P.S., Waxman D.J. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol 2001, 60(6):1268-1279.
20. Colvin O.M. Alkylating agents and platinum antitumor compounds. Cancer medicine 1997, 949-976. Williams & Wilkins, Baltimore. J.F. Holland, E. Frei, R.C. Bast, D.W. Kufe, D.L. Morton, R.R. Weichselbaum (Eds.).
21. Jurado J.M., Sanchez A., Pajares B., Perez E., Alonso L., Alba E. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 2008, 10(9):583-586.
22. Rosell R., Moreno I., Maestre J., Olazabal A., Carles J., Barnadas A., et al. Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall-cell lung cancer: a meta-analytic review. J Surg Oncol 1990, 45(2):124-130.
23. Ramakrishnan R., Gabrilovich D.I. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother 2011, 60(3):419-423.
24. Lake R.A., Robinson B.W. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005, 5(5):397-405.
25. Emens L.A. Chemoimmunotherapy. Cancer J 2010, 16(4):295-303.
26. Kepp O., Tesniere A., Schlemmer F., Michaud M., Senovilla L., Zitvogel L., et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009, 14(4):364-375.
27. Green D.R., Ferguson T., Zitvogel L., Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009, 9(5):353-363.
28. Ramakrishnan R., Assudani D., Nagaraj S., Hunter T., Cho H.I., Antonia S., et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010, 120(4):1111-1124.
29. Roses R.E., Xu M., Koski G.K., Czerniecki B.J. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene 2008, 27(2):200-207.
30. + T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 2006, 24(24):5119-5132.
31. Salem M.L., El-Naggar S.A., Cole D.J. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell Immunol 2010, 261(2):134-143.
32. Levesque J.P., Hendy J., Takamatsu Y., Simmons P.J., Bendall L.J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003, 111(2):187-196.
33. Granucci F., Zanoni I., Feau S., Ricciardi-Castagnoli P. Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. Embo J 2003, 22(11):2546-2551.
34. Serafini P., De Santo C., Marigo I., Cingarlini S., Dolcetti L., Gallina G., et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004, 53(2):64-72.
35. + T cells. J Clin Invest 2006, 116(10):2777-2790.
36. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006, 66(2):1123-1131.
37. + T cell tolerance in cancer. Nat Med 2007, 13(7):828-835.
38. Nagaraj S., Schrum A.G., Cho H.I., Celis E., Gabrilovich D.I. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010, 184(6):3106-3116.
39. Fernandez A., Mesa C., Marigo I., Dolcetti L., Clavell M., Oliver L., et al. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol 2011, 186(1):264-274.
40. Angulo I., de las Heras F.G., Garcia-Bustos J.F., Gargallo D., Munoz-Fernandez M.A., Fresno M. Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 2000, 95(1):212-220.
41. Liu C., Yu S., Kappes J., Wang J., Grizzle W.E., Zinn K.R., et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007, 109(10):4336-4342.
42. Salem M.L., Al-Khami A.A., El-Naggar S.A., Diaz-Montero C.M., Chen Y., Cole D.J. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol 2010, 184(4):1737-1747.
43. Movahedi K., Guilliams M., Van den Bossche J., Van den Bergh R., Gysemans C., Beschin A., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111(8):4233-4244.
44. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Fernandez Gomez A., Mesa C., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010, 40(1):22-35.
45. Ge Q., Hu H., Eisen H.N., Chen J. Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments. Proc Natl Acad Sci U S A 2002, 99(5):2989-2994.
46. Surh C.D., Boyman O., Purton J.F., Sprent J. Homeostasis of memory T cells. Immunol Rev 2006, 211:154-163.
47. Prlic M., Jameson S.C. Homeostatic expansion versus antigen-driven proliferation: common ends by different means?. Microbes Infect 2002, 4(5):531-537.
48. Pan L., Delmonte J., Jalonen C.K., Ferrara J.L. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995, 86(12):4422-4429.
49. Rutella S., Pierelli L., Bonanno G., Sica S., Ameglio F., Capoluongo E., et al. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 2002, 100(7):2562-2571.